{"commentary":{"count":5,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT04592237","nct_id":"NCT04592237","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04592237. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE: Patients receive niraparib orally PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Group I (niraparib)","type":"EXPERIMENTAL"},{"description":"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE: Patients receive cetrelimab IV over 30 minutes on day 1 and niraparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Group II (cetrelimab, niraparib)","type":"EXPERIMENTAL"}],"collaborators":["Janssen Pharmaceutica"],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Aggressive Variant Prostate Carcinoma","Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Metastatic Prostate Neuroendocrine Carcinoma","Metastatic Prostate Small Cell Carcinoma","Stage IV Prostate Cancer AJCC v8"],"enrollment":{"count":120,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cabazitaxel","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Cetrelimab","type":"BIOLOGICAL"},{"name":"Niraparib","type":"DRUG"}],"last_update":"2026-09-09","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival","timeFrame":"Time from randomization until documented disease progression, start of new therapy for prostate cancer in the absence of progression, or death in the absence of progression, whichever comes first, assessed up to 5 years"}],"references":[],"start_date":{"date":"2020-12-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04592237"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04592237"}